Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial is futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously disappointing, we decided to take a calculated risk on this program and with the carefully staged agreement, we have spent a total of $15 million, a relatively modest amount for a late Phase 3 asset addressing a large market opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain dedicated to advancing our development pipeline by making investments in future growth and continue to look for attractive late-stage in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a divis
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ) ... process of identifying a successor to Surya N. Mohapatra, Ph.D., ... has formed a search committee, engaged a leading executive recruitment ... Dr. Mohapatra has agreed to continue to serve ...
... 25, 2011 New England Research Institutes (NERI) today ... from the National Institutes of Health (NIH) for the ... (PHN). PHN is a multi-center clinical research network started ... Blood Institute (NHLBI) of the National Institutes of Health, ...
... SEATTLE, Oct. 25, 2011 Cell Therapeutics, Inc. ("CTI" or ... results for the third quarter ended September 30, 2011. ... Company as we move pixantrone one step closer to potential ... Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the ...
Cached Biology Technology:Quest Diagnostics Initiates CEO Succession Process 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 5Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 6
(Date:9/18/2014)... from McGill University and the Quebec government have ... Canadian Journal of Fisheries and Aquatic Sciences ... household cleansers, or industrial cleansers, to which they ... small size and buoyancy, they may readily pass ... global contaminant in the world,s oceans, but have ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... 2011 Neurotechnology , a provider of ... of MegaMatcher Accelerator 4.0 , the latest ... solution for high-volume, high-speed fingerprint and iris identification. ... enhanced fault tolerance and a new matching algorithm ...
... the Hawai,i Institute of Marine Biology (HIMB) have developed ... part of a hybrid web application titled GeoSymbio ... on symbiotic zooxanthellae called Symbiodinium which are ... other marine organisms like anemones, jellyfish, and corals. ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
Cached Biology News:Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 2Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 3Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 4An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3
Request Info...
... The integration of 2D polyacrylamide gel electrophoresis ... regarded as a core technology platform for ... power for complex samples limited only in ... small and large proteins. Quantitative image based ...
... Pfx DNA Polymerase is ideal for ... downstream applications such as cloning and ... by a proprietary enzyme preparation containing ... with proofreading (3'Cut Site5' exonuclease) activity. ...
... PLAU N-term Antibody This antibody is ... conjugated synthetic peptide selected within aa 50~150 ... supplied in PBS with 0.09% (W/V) sodium ... protein G column and eluted out with ...
Biology Products: